A New Hope?

A new study shows that total pancreatectomy with islet autotransplantation — sooner rather than later — can prevent the onset of diabetes and improve quality of life in patients with chronic pancreatitis.

MIND THE GAP:
Gender Pay Disparities

COMMUNITY SERVICE:
Can Telemedicine Improve Your Practice?
14 | **The Gender Gap**
Female endocrinologists are paid less than their male counterparts and they’re not alone. Will medicine — and endocrinology in particular — ever narrow the pay disparities between men and women as other professions outside healthcare have done?

BY GLENS FAUNTLEROY

10 | **A New Hope?**
Even though it has been around for 40 years to treat chronic pancreatitis, a new study shows that a total pancreatectomy with islet autotransplantation, sooner rather than later, can stave off the onset of diabetes and improve quality of life.

BY KELLY HORWATH

18 | **Long Distance Relationship**
A new way to deliver care via telemedicine has allowed one endocrinologist the ability to enhance his reach to patients he would otherwise never be able to treat...or even meet.

BY MATTHEW BOUCHONVILLE, MD

23 | **Heir Apparent**
Our expert panel takes a multi-faceted look at one of the most common inherited metabolic disorders, congenital adrenal hyperplasia.

BY NILS KRONE, MD, FRCPCH, RICHARD J. AUCHUS, MD, PHD, AND NICOLE REISCH, MD
4 | PRESIDENT’S VIEWPOINT
The key to member — and the Society’s — success

5 | FROM THE EDITOR
Introducing Endocrine News 2.0

6 | TRENDS & INSIGHTS
A look at the latest research on diabetes: control options, telephone intervention, impact on lymphatic vessels, and link of type 2 diabetes to risk of Alzheimer’s

30 | LABORATORY NOTES
Q&A: A PECULIAR TRAIT
Endocrine News talks to Márta Korbonits, MD, PhD, at the Queen Mary University of London about her research in seeking the mutations behind a familial adenoma.
BY MELISSA MAPES

33 | ADVOCACY
Bill to improve safety of personal care products, NIH Initiatives and Funding

36 | InTOUCH
Cushing’s CPG released, Society Participates in NICHD Advisory Council Meeting

41 | HORMONE HEALTH NETWORK
Fact Sheet: Shared Decision Making

43 | CLASSIFIEDS
Career opportunities

www.endocrine.org
I JOINED THE ENDOCRINE SOCIETY 25 YEARS AGO and have been involved in a variety of roles throughout the years, culminating with my current service as president. This journey has been very rewarding, as I have met many colleagues who are now friends, and I have learned from a wide variety of experiences along the way. This has been possible for me because many years ago when I first joined the Society I volunteered to serve on a committee. There are many opportunities available for members to participate on committees, subcommittees, focus groups, and task forces. I would encourage you to become involved — particularly those of you who are new trainees and early career professionals — as you are the future of our Society.

Committees and Task Forces
Each year the president-elect names nearly 100 members to committees, which is usually a three-year commitment. In addition, there are other ways to engage with the Society on a shorter-term basis, as part of a focused group formed to address a specific issue. A few months ago I convened task forces to address current needs in Leadership Development, Knowledge Integration, and ENDO, and this provided me a great opportunity to invite new members who had volunteered for committee service to participate. Increasingly, the Society will be reaching out to members who have expressed interest to involve them in working groups with short-term assignments, as well as focus groups to give feedback on ideas or existing products from the end-user perspective. I encourage you to volunteer and to take advantage of opportunities to provide your input. By giving your time and expertise to the Endocrine Society you will gain knowledge, learn new skills, and make connections that will be valuable assets for your professional career in the future. If you are interested, please visit: www.endocrine.org/volunteer

Recognizing Colleagues, Mentors, and Mentees
Each year, the Society presents more than $800,000 in awards to endocrinologists at all stages of their careers to recognize their dedication to excellence in research, education, and clinical practice in the field of endocrinology. The Awards Call for Nominations will launch this fall, and I encourage all of our members to participate in the nomination process to celebrate the accomplishments of your peers, mentors, and mentees. Please take the time to learn more about our awards at www.endocrine.org/awards and to submit your nominations. The selected awardees will be recognized at ENDO 2016 in Boston.

Election for Officers and Council
The ballot for the 2016 Endocrine Society election was sent on September 1. The Society governance is well balanced, and each year a president-elect, a vice president, and a council-designated seat are elected from one of the three constituencies — basic scientists, clinical scientists, and physicians-in-practice — with the candidates for each of the positions coming from a different constituency. The positions on the ballot for the 2016 election are:

- President-Elect (Clinical Scientist)
- Vice President (Physician-in-Practice)
- Council (one Basic Science seat and two At Large seats)

Our Society has an outstanding group of qualified candidates on the ballot, and I encourage all our voting members to participate in this very important activity. The officers and council members embrace the Society’s mission, vision, and strategic plan and provide thoughtful oversight and stewardship of the Society.

Please remember to cast your vote and remind your colleagues as well. This is your Society, and your participation in the election is important! If you have any questions or comments, you can reach me via president@endocrine.org.

Lisa H. Fish, MD
President, Endocrine Society
Endocrine News 2.0

WELCOME TO THE DEBUT OF THE REFRESHED ENDOCRINE NEWS!

As you thumb through this issue, it will be obvious that there has been a significant design overhaul. We felt this “reboot” vital in order to make Endocrine News a more viable vehicle for how readers receive information. The goal is to present the content in a contemporary and reader-friendly context because magazines should be dynamic with a need to evolve. That’s what we’re doing with Endocrine News. It’s had a very similar look for the last several years, and now it’s time to present a publication that can deliver noteworthy content in a manner that appeals to our audience while also reflecting current design standards. Also, a special thanks to the designer of this new look, Catherine Neill Juchheim of CNJ Creative, LLC. Bravo!

But the change will be gradual. While the refreshed design is officially being unveiled in this issue, the coming months will see a few new surprises peppered in amongst the magazine’s familiar features. One new type of article is the First Person feature, “Long Distance Relationship” on page 18, written by Matthew Bouchonville about his experiences in working with Endo ECHO in rural New Mexico. He details how he’s been able to connect with patients — and other healthcare professionals — via telemedicine. Bouchonville says the experience has made him a better doctor. “By sharing my expertise as an endocrinologist and working as part of a multi-disciplinary team to mentor primary care providers in rural and underserved communities, I’m helping more patients with diabetes and other endocrine conditions get the care they need and live healthier lives,” he writes.

These First Person articles are a new addition to the line-up, and they will require input from you, the members of the Endocrine Society. We want to use these articles as a way for you to tell your day-to-day stories of working in the field of endocrinology. Whether you’re a scientist in a lab, a clinician treating patients, or a researcher in the clinic, we want you to share your experiences with our more than 22,000 readers. So if you have a story you’d like to share with your endocrinology brethren, feel free to send me an email at mnewman@endocrine.org.

This month’s cover story, “A New Hope,” by Kelly Horvath (p. 10) concerns treating chronic pancreatitis with a total pancreatectomy with islet autotransplantation, based on a study and editorial published in the May issue of The Journal of Clinical Endocrinology & Metabolism. Essentially, it was revealed that if this procedure is performed sooner, rather than later, the the patient could maintain a better quality of life; plus the risk of diabetes onset was significantly reduced.

AGAIN, enjoy the “remodeled” Endocrine News, and please let me know your thoughts and comments on the redesign.

— Mark A. Newman, Editor, Endocrine News
Laparoscopic adjustable gastric band (LAGB) surgery and an intensive medical diabetes and weight management (IMWM) program have similar one-year benefits on diabetes control, cardiometabolic risk, and patient satisfaction, according to a study recently published in the *Journal of Clinical Endocrinology & Metabolism*.

Researchers led by Allison B. Goldfine, MD, of the Joslin Diabetes Center at Harvard Medical School, noted that surgical recommendations, as opposed to lifestyle changes and pharmacological interventions, for treating type 2 diabetes (T2D) remain controversial. So Goldfine and her team set out to compare the two approaches.

In a 12-month, randomized clinical trial the researchers compared 23 people undergoing LAGB surgery to 22 people participating in an IMWM program. The subjects were “aged 21 – 65 years with body mass index of 30 – 45 kg/m2, T2D diagnosed more than 1 year earlier, and glycated hemoglobin (HbA1c) 6.5% on antihyperglycemic medication(s).” After randomization, five participants did not undergo surgery. “Seven of the 18 LAGB and eight of the 22 IMWM participants had BMI below 35 kg/m2,” the authors write. “Of those that initiated intervention, three missed 12-month assessments due to time constraints, and one moved out of state. Twelve-month retention rates were 94% in the LAGB group and 82% in the IMWM group.”

The proportion of patients who met the primary glycemic endpoint (HbA1c 6.5% and fasting glucose 7.0 mmol/L at 12 months, on or off medication) was 33% in the LAGB group and 23% in the IMWM group. HbA1c reduction was similar in both groups and three and 12 months, and weight loss was similar in both groups at three months but greater in the LAGB group at 12 months. “Systolic blood pressure reduction was greater after IMWM than LAGB, whereas changes in diastolic blood pressure, lipids, fitness, and cardiovascular risk scores were similar between groups,” the researchers write. “Patient-reported health status, assessed using the Short Form-36, Impact of Weight on Quality of Life, and Problem Areas in Diabetes, all improved similarly between groups.”
Certain patients with type 2 diabetes (T2D) may have specific genetic risk factors that put them at higher risk for developing Alzheimer’s disease (AD), according to a study conducted at and published recently in *Molecular Aspects of Medicine*.

Researchers led by Giulio Maria Pasinetti, MD, PhD, of the Icahn School of Medicine at Mount Sinai in New York City used recent genome-wide association study (GWAS) findings to investigate whether T2D and AD share common genetic etiological factors and the potential impact of these genetic factors on the cellular and molecular mechanisms that may contribute to the development of both these diseases.

GWAS look at differences at many points in the genetic code to see if, across a population, one or more variations in the code are found more often in those with a given trait (for example, high risk for a disease). Even the smallest genetic variations — called single nucleotide polymorphisms (SNPs) — can have a major impact on a trait by swapping just one of the 3.2 billion “letters” that make up the human DNA code.

The researchers retrieved SNPs associated with T2D and AD from large-scale GWAS meta-analysis and tested for any overlap. “We then explored the function of the shared T2D/AD GWAS SNPs by leveraging expressionnal quantitative trait loci, pathways, gene ontology data, and co-expression networks,” they write. “We found 927 SNPs associated with both AD and T2D with p-value ≤0.01, an overlap significantly larger than random chance (overlapping p-value of 6.93E-28). Among these, 395 of the shared GWAS SNPs have the same risk allele for AD and T2D, suggesting common pathogenic mechanisms underlying the development of both AD and T2D.”

The authors conclude that their study tentatively supports epidemiological observation of disease concordance between T2D and AD. “Moreover,” they write, “the studies provide the much-needed information for the design of future novel therapeutic approaches, for a subpopulation of T2D subjects with genetic disposition to AD, that could benefit T2D and reduce the risk for subsequent development of AD.”

**Findings:** “We identified multiple genetic differences in terms of SNPs that are associated with higher susceptibility to develop type 2 diabetes as well as Alzheimer’s disease,” Pasinetti says. “Many of these SNPs are traced to genes whose anomalies are known to contribute to T2D and AD, suggesting that certain diabetic patients with these genetic differences are at high risk for developing Alzheimer’s. Our data highlights the need for further exploration of genetic susceptibility to Alzheimer’s disease in patients with T2D.”
For the first time, researchers have identified how type 2 diabetes (T2D) affects lymphatic vessels — a finding that could lay the groundwork for new therapies to improve the lives of people with the condition, according to a study recently published in *Cardiovascular Research*.

The scientists, led by Joshua Scallan, PhD, of the University of Missouri, examined the lymphatic integrity of transgenic mice and developed a new assay that “quantifies the solute permeability of murine collecting lymphatic vessels,” since studying lymphatic vessel function in animals has been a challenge for researchers, because unlike blood vessels, lymph vessels are clear and appear almost invisible. They write, “When compared to age-matched wild-type (WT) controls, the permeability of collecting lymphatics from diabetic, leptin receptor-deficient (db/db) mice was elevated >130-fold. Augmenting nitric oxide (NO) production by suffusion of L-arginine rescued this defect. Using pharmacological tools and eNOS−/− mice, we found that NO increased WT lymphatic permeability, but reduced db/db lymphatic permeability. These conflicting actions of NO were reconciled by the finding that phosphodiesterase 3 (PDE3), normally inhibited by NO signaling, was active in db/db lymphatics and inhibition of this enzyme restored barrier function.”

“When an individual has type 2 diabetes, cells in the lymphatic vessels aren’t producing enough nitric oxide, which is essential to maintaining the integrity of their endothelial layer so that they function properly,” Scallan says. “We found that by giving the lymphatic vessels L-arginine, an amino acid commonly found in red meat, poultry, dairy products, and nutritional supplements, we were able to boost their nitric oxide production and restore their ability to act as a barrier.”

**Findings:** The authors conclude that they have identified the first lymphatic vascular defect in T2D, as the disease causes an enhanced permeability due to low NO bioavailability. “Further,” they continue, “this demonstrates that PDE3 inhibition is required to maintain lymphatic vessel integrity, and represents a viable therapeutic target for lymphatic endothelial dysfunction in metabolic disease.”

---

**Impact of Type 2 Diabetes on Lymphatic Vessels Identifed**

Periodic telephone counseling can be a highly effective, low-cost tool for lowering blood-sugar levels in minority, urban adults with uncontrolled diabetes, according to a study recently published in the *American Journal of Preventive Medicine*.

Researchers led by Elizabeth A. Walker, PhD, RN, of the Albert Einstein College of Medicine in New York, analyzed 941 adults with diabetes living in the South Bronx. Participants were predominantly Latino (68%) or non-Latino black (28%), with 70% foreign born and 55% Spanish speaking, all recruited through the New York City Department of Health and Mental Hygiene (Health Department) A1c Registry.
All 941 adults were mailed printed diabetes self-management materials. Additionally, half (443) were randomized to receive telephone calls from the Health Department health educators about the importance and rationale for adhering to their medication regimens, maintaining good nutrition and exercising. Telephone-group participants who had moderately elevated blood A1c levels (between 7% and 9%) could receive up to four phone counseling sessions over one year; those with extremely elevated A1c levels (above 9%) could receive up to eight calls. After one year, the researchers assessed participants’ A1c change through the A1c Registry.

The greatest difference in A1c levels involved people who initially had extremely elevated A1c levels: For those getting telephone intervention (completing an average of 6.3 calls), their A1c levels decreased an average of 2.1% (from 11.3% to 9.2%) versus an average decrease of 1.3% among print-only group individuals with extremely elevated A1c levels (from 11.0% to 9.7%). Phone calls were less helpful for people in the moderately elevated A1c group — possibly because they completed too few phone-counseling sessions (an average of 3.4 calls). On average, their A1c levels didn’t change over the course of the year, while A1c levels increased by 0.2% (from 7.8% to 8.0%) among print-only participants with moderately elevated A1c levels. Overall, those in the telephone group decreased their A1c by 0.4% more than those in the print-only group.

**Findings:** The authors conclude that “a telephone intervention delivered by health educators can be a clinically effective tool to improve diabetes control in diverse populations, specifically for those with worse metabolic control identified using a registry.” They also note that the findings are particularly important as they demonstrate the value of an intervention that is culturally sensitive and individually tailored for a low-income and non-English speaking population.

---

**SKIN CARE IS AN ESSENTIAL PART OF SELF CARE.**

Introducing **EUCERIN DIABETICS’ DRY SKIN RELIEF:** Noticeably moisturizes skin after just one use with an effective formulation of urea and alpha hydroxy acids.

©2015 Beiersdorf Inc.
Even though it has been around for 40 years to treat chronic pancreatitis, a new study shows that a total pancreatectomy with islet autotransplantation, sooner rather than later, can stave off the onset of diabetes and improve quality of life.
These dire prognoses are not necessarily the case any longer, due to the enormous success of the nearly 40-year-old procedure known as total pancreatectomy with islet autotransplantation (TP/IAT). The twofold problem is, many clinicians are unaware that the procedure exists, and many of those who do know about it mistakenly believe that they do not have access to a facility that can implement it.

**A NEW LEASE ON LIFE**

In the May 2015 issue of *The Journal of Clinical Endocrinology & Metabolism (JCEM)*, the manuscript entitled “Factors Associated With Islet Yield and Insulin Independence After Total Pancreatectomy and Islet Cell Autotransplantation in Patients With Chronic Pancreatitis Utilizing Off-site Islet Isolation: Cleveland Clinic Experience,” reveals just how mistaken that latter notion is. “In our study, we show that patients can get this care at a lot of places without too much cost involved,” says the article’s lead author, Betul A. Hatipoglu, MD, in the Department of Endocrinology, Diabetes and Metabolism at the Cleveland Clinic Foundation in Ohio. “We improved both quality of care and patient QOL in the long term, and we are very happy about that.”
Without islet transplantation, total pancreatectomy invariably causes diabetes. Although the patient’s pain may wax and wane, in a large segment of patients with chronic, relentless pain, overall QOL will continue to deteriorate due to chronic pain, narcotic addiction, weight loss, diarrhea, and general disability. As a result of the inflammatory process in the pancreas, islet destruction ensues and the islet mass diminishes, leading ultimately to diabetes. TP/IAT removes the patient’s own islets from the resected pancreas and transplants them into the patient’s liver. This effectively gives the patient a new lease on life. But because laboratories that are equipped to isolate the islet cells from the removed pancreas are very expensive to establish and therefore scarce, TP/IAT has been regrettably underutilized.

To reverse this unfortunate and unnecessary trend, Hatipoglu and team sought to determine whether the IAT component of TP/IAT could be conducted off-site — in this case at the University of Pittsburgh’s islet isolation lab. In a cohort of 18 male and 18 female patients averaging age 38 years, they achieved rates of islet yields and insulin independence commensurate with those centers with on-site labs report, about 33%. “The most important point I want to get out there is that it would be impossible and not at all cost effective for every institution performing pancreatectomies to run an islet isolation lab,” Hatipoglu says. “With our study, we were able to show that collaborating with another lab capable of isolating the islets for us yielded very similar outcomes, which means that one lab can serve many hospitals. This kind of networking will allow clinicians to serve their patients the best possible way. Not every patient can afford to go to one of the larger centers, and we showed that it is okay to treat them locally.”

DON’T WAIT TO OPERATE

In “Total Pancreatectomy and Islet Autotransplantation for Chronic Pancreatitis: Breaking Down Barriers,” an accompanying editorial by JCEM editor-in-chief, R. Paul Robertson, MD, at the University of Washington in Seattle, the cause of publicizing the success and accessibility of TP/IAT is further heralded. “Transplantation centers should understand that they do not need their own islet isolation facility and can learn how to work with an existing one — like the Cleveland Clinic has done with the University of Pittsburgh. That demonstration opens the door — because now, when healthcare providers make the diagnosis of chronic, irreversible pancreatitis, they can realistically consider taking the entire pancreas out.” In other words, delaying the procedure — which was once considered routine for this disease — is not going to improve anything and could potentially make the patient’s condition much worse. The patient will continue to suffer pain and disability.

Another reason not to wait to operate is that the ultimate outcome of [chronic pancreatitis] is diabetes in most cases. That is not a great reward at the end of the road. My message is, get [total pancreatectomy with islet autotransplantation] done as soon as you realize that the disease course is chronic and irreversible to relieve pain — that is the main reason — but also to prevent diabetes.”

— R. PAUL ROBERTSON, MD, EDITOR-IN-CHIEF, THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
as long as the pancreas stays inside the body. Moreover, many of these patients have been forced to leave their jobs or forfeit care of their families because of the debilitating nature of their disease.

"Another reason not to wait to operate is that the ultimate outcome of CP is diabetes in most cases. That is not a great reward at the end of the road," Robertson says. "My message is, get [TP/IAT] done as soon as you realize that the disease course is chronic and irreversible to relieve pain — that is the main reason — but also to prevent diabetes.” Although no strict definition of “irreversible course” exists, what Robertson calls “clinical common sense” indicates that the condition of a pancreatitis patient with significantly reduced QOL for the prior couple of years is likely going to worsen, leaving no good reason to try to retain the pancreas. "Some surgeons will take out progressively more of the pancreas over time, but each time they take out a little more, the patient is that much closer to diabetes. Those surgeons are not just removing the inflamed non-islet tissue, they are also taking out functional islets with each piece of the pancreas," he says.

Hatipoglu agrees that delaying can mean a less favorable outcome for the patient. “If you are too late, then the patient’s pain management might not be as good as if the procedure had been done earlier, and the islet mass will not be in great shape. Timing of the surgery is therefore very important and should be a decision made by a multidisciplinary team,” she says.

The bottom line is, there appears to be no good reason not to perform TP/IAT with a chronic, irreversible disease course and several important reasons in favor of doing it. It can resolve the pain and reduced QOL associated with CP, it is becoming widely accessible in terms of location and cost, and it prevents the eventual downs in diabetes the patient would otherwise likely face. “[TP/IAT] is gaining momentum, but this snowball needs to roll down the hill a little faster,” Robertson says. Patients should not have to suffer unnecessarily, and the healthcare system could certainly benefit from a lighter diabetes burden. ©

HORVATH IS A FREELANCE WRITER BASED IN BALTIMORE, MD. SHE WROTE ABOUT ENDOCRINE-DISRUPTING CHEMICALS’ EFFECTS ON FEMALE REPRODUCTION IN THE JULY ISSUE.
Female endocrinologists are paid less than their male counterparts, and they’re not alone. Will medicine – endocrinology in particular – ever narrow the pay disparities between men and women as other professions have done?
It is no secret that women are often paid less than their male counterparts in the same position. The Equal Pay agenda has made significant news since the White House first revealed that full-time working women earn only about 77 cents for every dollar a man earns.

The gender pay gap spans across almost every profession and doesn't skip the salaries paid to endocrinologists. In 2014, male endocrinologists earned an average salary of $206,000 compared with the $168,000 earned by female endocrinologists, according to the "Medscape Endocrinologist Compensation Report 2015."

“There is no doubt that women endocrinologists are paid less than men,” says Mary Lee Vance, MD, professor of Medicine, Endocrinology and Metabolism at the University of Virginia School of Medicine in Charlottesville. “I've observed this for over 30 years.”

The trend of less pay for female physicians stretches across all specialties. A 2013 study in JAMA Internal Medicine reported female physicians earned an average $56,000 less each year than male physicians — a gap that researchers found hasn't moved since the late 1980s.

Harvard Medical School researchers examined nationwide salaries from 1987 to 2010 and revealed salary earnings of male physicians steadily exceeded female physicians by 25%. Over those same years, however, the salary gap between women and men outside of healthcare shrunk from 28% to 15%.

“There is something that’s intrinsically going on within the physician workforce,” study author Anupam Jena, PhD, told Reuters.
“ALTERNATIVE FACTORS”

When the White House released the National Equal Pay Task Force report in 2013, several articles were subsequently issued that offered the counter-argument. The consensus was that while there is indeed a gap in salaries between men and women, the gap wasn’t nearly as great as 77 cents on a dollar.

Some economists and policy analysts also argued that “alternative factors” should be recognized as the reason for pay differences. Education, choice of occupation, hours worked, experience, and career interruptions all affect the compensation of workers, whether male or female, according to the Equal Pay for Equal Work issue brief released last year by The Heritage Foundation.

Craig Fowler, president of the National Association of Physician Recruiters, agrees and says that in his nearly 20 years of physician recruiting he’s never had a search where less money was offered to a woman than a man for the same job. “Base compensation is always the same regardless of gender,” Fowler explains. “Differences may come into play when it comes to productivity pay.”

“It is possible that female physicians earn less in productivity compensation due to outside responsibilities, such as family and children that pull on their time,” he continues. “Females may not work as many hours as men, therefore, see fewer patients and consequently earn less in production dollars.”

The Medscape report backs Fowler’s sentiment. It noted that women tend to work shorter hours and fewer weeks than men, revealing that 18% of female endocrinologists work part time compared with 7% of male endocrinologists. Family obligations are the main reasons.

Susan Herzlinger Botein, MD, of Boston’s Joslin Diabetes Center, agrees that working women have more challenges and obligations at home but acknowledges there are “plenty of stay-at-home dads who allow female physicians who prefer to work full-time to do so.”

“In the absence of that, because of the time demands of paperwork and documentation, ‘full time’ clinical work invariably is completed in so-called off hours,” says Botein. “Due to the demands and pleasure of having a family, full-time clinical work does not work for many of us. I feel fortunate to be able to spend time with my young children and hope that this also makes me a better and happier physician.”

So, does gender discrimination in healthcare play a role in salary differences or career advancement? Most female physicians say yes. Rock Health, a healthcare venture funding group, surveyed 400 female physicians and found that women feel gender continues to hold them back. In fact, 96% believed gender discrimination still exists. In Rock Health’s “The State of Women in Healthcare,” 40% of female respondents also believed their firms do not support women in career development.
WOULD YOU DO IT ALL OVER AGAIN?

The Medscape report revealed other facts about the endocrinology specialty. Endocrinologists are among the lowest-paid physicians, ranking third from the bottom. On average, endocrinologists earned $196,000 annually — placing the specialty just above family medicine and pediatrics as the lowest wage earners.

Where endocrinologists’ work does make a difference is in earning power. Those in office-based single-specialty group practices make the most ($222,000), with endocrinologists in outpatient clinics ranking second at $208,000. Those in the specialty earning the least are in academic or government settings ($186,000) and hospitals ($162,000). With these numbers in mind and noting the gender pay differences, only 38% of female endocrinologists reported being satisfied with their income — lower than the 45% reported by their male counterparts.

“I am not satisfied or accepting of the inequity in salary compared with my male colleagues,” says Vance. “This element of inequitable remuneration does impact on the issue of ‘satisfaction,’ including my experience. Why are women paid less than men for the same work? There is no excuse for this.”

But if they had to do it all over again, 63% of endocrinologists said they would still choose medicine as a career, although less than half (45%) would follow the path of endocrinology once more.

“I think that physicians who would not pursue their specialty are dissatisfied with how their choice fits into their lifestyle, such as the time demands, administrative burden, and income,” says Botein. “These factors are, appropriately, not the focus of medical school and residency but can be a surprise. Further, peoples’ lives change quite a bit in their 20s and 30s, when these decisions are made,” she adds. “It’s easier to say ‘who needs money?’ when you are single without children. I have not second-guessed my career path into endocrinology.”

Women in the Medscape survey also differed from men when describing what they find most rewarding about their jobs. Among endocrinologists, 42% of men and 36% of women believe that relationships with patients are a major source of satisfaction. Vance says that she is very satisfied with her career in academic medicine and finds patient care and education of the medicine residents, medical students, and her endocrine fellows most rewarding.

Botein agrees. “I feel fortunate to have chosen a specialty that I find intellectually satisfying and allows close, long-term relationships with my patients. That my job fits into the structure of my family life is not accidental.”

Fowler says for female physician job seekers who are looking to leave a current position, the main reason is to be closer to family. “Secondly, I see improved quality of life as another reason, such as hours, call schedule, and volume of patients.”

GLENDA FAUNTLEROY IS A FREELANCE WRITER BASED IN CARMEL, IND., AND A REGULAR CONTRIBUTOR TO ENDOCRINE NEWS. SHE WROTE ABOUT HYPOPHOSPHATASIA IN THE AUGUST ISSUE.

ENDOCRINE NEWS | SEPTEMBER 2015 | 17

THE GENDER GAP

AT A GLANCE

▸ In 2014, male endocrinologists earned an average salary of $206,000 compared with the $168,000 earned by female endocrinologists.

▸ Some economists and policy analysts argue that “alternative factors” should be recognized as the reason for pay differences.

▸ A survey of 400 female physicians found that women feel gender continues to hold them back.

CHANGE TO COME?

Fifty years after the passage of the 1963 Equal Pay Act, the Obama administration’s Equal Pay Task Force is working to permanently close the gender pay gap. The very first bill signed into law by the president was the Lilly Ledbetter Fair Pay Act, which extended the time period in which claimants can bring pay discrimination claims.

Since then, a number of other initiatives, including pay data collection and addressing discrimination against mothers and caregivers, have been underway.

▸ More information on what’s being done can be found at www.whitehouse.gov.
A new way to deliver care via telemedicine has allowed one endocrinologist the ability to enhance his reach to patients he would otherwise never be able to treat…or even meet. Matthew Bouchonville, MD, an endocrinologist at the University of New Mexico, shares his experiences with Endo ECHO and its impact in rural New Mexico.

Every Wednesday at noon, my colleagues and I gather around a U-shaped conference table in front of two giant flat-screen TVs. One by one, the faces of our community partners pop up: primary care doctors, nurses, physician assistants, and community health workers from nine federally qualified health centers (FQHCs) across New Mexico.

Here, at our “hub” in Albuquerque at the University of New Mexico, we have at the table an adult endocrinologist (me), a pediatric endocrinologist, a nephrologist, a pharmacist, a psychiatrist, a nurse manager, a community health worker, and a social worker. For the next two hours, we listen and ask questions as the primary care teams at the FQHCs present their cases of patients who have diabetes.

We don’t see these patients directly. Yet, by “telementoring” our FQHC colleagues, we are helping to ensure that they receive excellent, comprehensive care for their conditions from trained providers in their home communities, instead of having to wait for months and drive for hours to see us, the specialists.

A MEANINGFUL SOLUTION

Approximately 30 million people in the U.S. have diabetes, and 40% of those cases are uncontrolled. Although diabetes is a manageable disease, our healthcare system is struggling to meet the demand for care at a time when the number of endocrinologists is shrinking.
Matthew Bouchonville has been a faculty member of the University of New Mexico School of Medicine Division of Endocrinology, Diabetes, and Metabolism since 2011. As medical director of Endo ECHO, he mentors multiple clinicians in underserved communities around the state in collaboration with a multidisciplinary panel of experts to leverage scarce specialty resources to the front lines of community care. Bouchonville’s goal is to improve access to care for all patients with diabetes and other metabolic conditions by sharing the lessons learned from Endo ECHO with academic medical centers around the world. He is a 2006 graduate of the Eastern Virginia Medical School Medical College and is fluent in Spanish and Vietnamese (in addition to English).
I'm now part of a meaningful solution to that problem. It's an exciting new approach to care delivery that we're calling "Endo ECHO," and it has made me a better doctor. (ECHO stands for Extension for Community Healthcare Outcomes and is a collaborative model of medical education and care management that empowers clinicians to provide better care to more people, right where they live.)

By sharing my expertise as an endocrinologist and working as part of a multi-disciplinary team to mentor primary care providers in rural and underserved communities, I'm helping more patients with diabetes and other endocrine conditions get the care they need and live healthier lives. I'm actually reaching exponentially more patients than I do by seeing patients one on one. And the care, I believe, is better, because it is informed by specialists across disciplines — in real time. During our Endo ECHO clinics, we discuss not only whether a patient's blood glucose is under control but also whether he or she has depression, taking prescription medications for comorbid conditions, has adequate home support, and other aspects of his life.

**PATIENT GOALS**

By bringing the perspectives of a range of professionals together all at once to bear on patient care recommendations, we not only expand access to specialty care, but we also expedite the entire treatment process. For a patient to get referrals and appointments for each of these specialists separately would probably take months.

Most importantly, during the weekly teleclinics, we ask our community partners to tell us about their patients' goals. What is most important to the patient?

This is a question that too often gets lost in the disease management process. Before I began participating in Endo ECHO, my treatment was oriented around my goals as a doctor. But when patients have significant psycho-social barriers — as so many patients with diabetes do — it's important for doctors to step back and consider their patients' priorities so that they can guide them toward self-management in ways that fit their lives. Otherwise you might never achieve your goals as a doctor for your patient. And then the patient is labelled as non-compliant.

For example, in my own practice, I recently saw a patient with type 2 diabetes who wasn't self-managing. Instead of counseling her about non-compliance, I asked her about her life. And I listened.

It turned out that she's taking care of a father with Alzheimer's, as well as a son who has depression. By the time we finished our conversation, she realized that, in order to take care of others, she needed to take better care of herself. Before Endo ECHO, I would not have had that conversation.
SUPPORTING FRONT-LINE PROVIDERS

But the real power of Endo ECHO is at the community level, among front-line providers who previously struggled to keep up with new diabetes technologies, had difficulty accessing specialty expertise in a timely manner, and generally had little support.

Through Endo ECHO, these primary care providers are newly empowered: They belong to an ongoing learning network; they are constantly exposed to best practices; and they have mentoring relationships with a team of specialists who are also available to them outside the weekly teleclinics.

All this is particularly helpful in managing patients with type 1 diabetes, where changing technology plays such an important role.

In addition, each FQHC in Endo ECHO is paired with a community health worker whose job is to help patients navigate their psycho-social issues and act as their advocate. The community health workers are essential members of the Endo ECHO team because of their close relationships with their patients and insights into their patients’ everyday lives and challenges.

Like all doctors, I went into medicine to do good. Through Endo ECHO, I am part of a movement, practicing medicine in a way that I never dreamed of doing, collaboratively, in a community of free and ongoing knowledge-sharing, for the benefit of patients I will never know, or even see.
Autoimmune Diagnostics

For nearly 30 years, KRONUS has provided specialized immunoassay test kits to medical professionals at the world’s most respected laboratory facilities. Our current product offering encompasses test kits for measurement of the following:

**NEUROIMMUNOLOGY**
- Acetylcholine Receptor Antibody (AChRAb):
  - Binding Antibody
  - Blocking Antibody
- Voltage-Gated Calcium Channel Antibody (VGCCAb)

**ISLET CELL AUTOIMMUNITY**
- Glutamic Acid Decarboxylase Antibody (GADA)
- Zinc Transporter 8 Autoantibody (ZnT8Ab)
- IA-2 Autoantibody (IA-2Ab)
- Insulin Autoantibody (IAA)

**THYROID**
- Thyroglobulin Antibody (TgAb)
- Thyroid Peroxidase Antibody (TPOAb)
- TSH Receptor Antibody (TRAb)
- Serum Thyroglobulin (Tg)

**ADRENAL AUTOIMMUNITY**
- 21-Hydroxylase Antibody (21-OHAb)

To obtain additional information on KRONUS’ unique line of laboratory test kits, please call us toll-free at **800 4 KRONUS** or email us at **kronus@kronus.com**.

**ALSO AVAILABLE FOR RESEARCH APPLICATIONS**
- Interferon-Omega Autoantibody (IFN-ωAb)†
- Aquaporin-4 Autoantibody (AQP4Ab)†
- Voltage-Gated Potassium Channel Antibody (VGKCA)†
- Titin Antibody (TitinAb)†
- GAD/IA-2 Antibody Screen†

† For Research Use Only. Not for use in diagnostic procedures.
Congenital adrenal hyperplasia (CAH) ranks among the most common inherited metabolic disorders, with the classic form (i.e., 21-hydroxylase deficiency) affecting about one in 15,000 newborns. It is characterized by a complex imbalance of steroid hormones, with reduced cortisol and aldosterone synthesis and excessive adrenal androgen production. Neonatal screening programs in most industrialized countries now enable early diagnosis in classic CAH and timely introduction of hormone substitution treatment. While this reduces life-threatening salt-wasting crises in newborns, hormone substitution over a lifetime poses new challenges in adult patients.

In this Tri-Point article, a basic researcher provides insights from model organism for altered adrenal steroid production, a clinical researcher discusses medical treatment options and challenges for adult patients with CAH, and a clinical practitioner highlights fertility-related challenges in adult CAH patients.
A Basic Researcher’s Perspective
— NILS KRONE, MD, FRCPCH*

Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders leading to impaired glucocorticoid biosynthesis. The clinical presentation of different CAH forms depends on the underlying enzymatic defect. Deficiencies of 21-hydroxylase (CYP21A2) and 11β-hydroxylase (CYP11B1) only affect adrenal steroid hormone biosynthesis, whereas 17α-hydroxylase (CYP17A1) deficiency and 3β-hydroxysteroid dehydrogenase type 2 (HSD3B2) deficiency also impair gonadal steroid production. P450 oxidoreductase deficiency (POR) presents with apparent combined CYP17A1-CYP21A2 deficiency. In addition, POR also causes skeletal malformations and severe genital ambiguity in both sexes. Traditionally, three further enzymatic deficiencies are classified within the CAH group. Steroidogenic acute regulatory protein (StAR) deficiency leads to a lipid adrenal and gonadal lipid accumulation resulting in Lipoid CAH (CLAH). P450 side-chain cleavage (CYP11A1) deficiency resembles the CLAH clinical presentation; however, patients have normal-sized or absent adrenals. Aldosterone synthase (CYP11B2) deficiency manifests with isolated mineralocorticoid deficiency and normal glucocorticoid synthesis.

Genetics of 21-Hydroxylase Deficiency
In clinical practice, the term CAH is often synonymously used for 21-hydroxylase deficiency (21OHD). 21OHD is caused by mutations in the CYP21A2 gene and accounts for about 95% of CAH cases in the general population. The majority of CYP21A2-inactivating mutations are caused by intergenic recombinations within the RCCX module. CYP21A2 gene deletions and CYP21A1P/CYP21A2 chimeric genes account for approximately 20% to 25% of 21OHD alleles in most Caucasian populations. About 70% to 75% of 21OHD disease-causing alleles originate from gene conversions with the CYP21A1P pseudogene, leading in small genetic transfers and single point mutations. The most common CYP21A1P-derived mutations include seven point mutations, a deletion of eight base pairs in exon 3, and the E6 cluster mutation. In addition to these common mutations, more than 150 pseudogene-independent mutations have been reported. The majority of these mutations occur sporadically and have only been reported in a small number of patients.

Genotype-Phenotype Correlation
Soon after the characterization of the CYP21A2 gene and the detection of disease-causing mutations, in vitro expression studies using insect and mammalian cells as well as yeast systems have been employed to assess the residual in vitro 21-hydroxylase function of common CYP21A2 mutations. These residual activities have built the framework for establishing the genotype-phenotype correlation in patients with CAH. This has been widely adopted to report population studies on 21-hydroxylase deficiency. Mutations are categorized into different mutation groups resembling: Null (mutations predicting absent in vitro activity), A (intron 2 splice site mutation), B (mutations such as the p.I172N mutation and mutations with 1% to 10% in vitro residual enzyme activity), C (mutations such as p.P30L, p.V281L, and p.P453S or above 20% to 30% in vitro 21-hydroxylase activity).

Overall, about 65% to 75% of patients with 21OHD are compound heterozygote. Commonly, the clinical phenotype is determined by the mildest CYP21A2 mutation, consequently allowing for the highest residual enzyme activity. Patients with Null and A genotypes have a high likelihood to present with salt-wasting (SW) CAH, whereas two-thirds of patients with group B genotypes present with simple-virilising (SV) CAH. Patients with group C genotypes commonly have non-classic (NC) CAH. Overall, genotype-phenotype data have supported genetic counselling; however, the best correlation has been found with the degree of renal salt loss. A limitation of pure in vitro enzyme analysis is the fact that pathophysiologic changes such as hyperplasia of the adrenal cortex cannot be modelled. This, in addition to other disease modifiers, might explain some of the observed variability of the expressed phenotype in patients with partially inactivating CYP21A2 mutations.
In times of more powerful genetic analysis methodologies such as next generation sequencing, modelling of genetic variants, and disease modifiers, it is becoming increasingly important to understand the clinical consequences.

The same principle establishing the in vitro activity of genetic variants has been applied in rarer deficiencies leading to CAH. Over the last five to 10 years, complete and partial mutations have been also described in all other forms of CAH where classic and non-classic presentations are now well established.

**Animal Models of CAH**

A naturally occurring Cyp21a2 deficient mouse was identified soon after the cloning of the human CYP21A2 gene. Further molecular characterization demonstrated loss of the active Cyp21a1 gene by unequal crossing over between the active Cyp21a1 gene and its pseudogene (Cyp21a2-p) leading to a chimeric Cyp21a1-Cyp21a2-p gene including a partial deletion of Cyp21a1. This chimeric gene carries several pseudogene-derived point mutations, missense mutations, and a nonsense mutation. The in vitro expression analysis of these mutations demonstrated lack of function of this chimeric gene. Overall, the Cyp21a2-deficient mice have been proven to be difficult to maintain postnatally, limiting their use as translational model. Another limitation modelling CAH is the lack of adrenal 17-hydroxylase expression in mice and consequently the lack of androgen excess in the 21-hydroxylase deficient mouse. However, further analysis of adrenals and metanephrine concentrations in these mice demonstrated severe impairment of adrenomedullary function in 21-hydroxylase deficiency. This led to further exploration of the human pathophysiology of CAH showing similar alterations of the adrenal gland in human patients with CAH. Interestingly, the severity of adrenomedullary function is closely correlated with the severity of the CYP21A2 genotype in humans.

Murine models of other CAH forms have been developed. The 11-hydroxylase (cyp11b1) null mouse showed glucocorticoid deficiency and mineralocorticoid excess, adrenal hyperplasia, and mild hypokalemic hypertension as well as glucose intolerance. Remarkably and contrary to humans, affected female mice were found to be infertile. The murine deletion model of the steroidogenic acute regulatory protein (STAR) showed a very high similarity to humans affected with the classic form of CLAH due to STAR mutation. Similar to humans suffering from CLAH, these mice also showed a considerable heterogeneity in the presentation and onset of adrenal insufficiency. The exact mechanisms explaining this variability remains to be elucidated. A similar severe phenotype was observed in the murine deletion model of P450 side chain cleavage model (Cyp11a1). These mice survived to term and then soon died after birth from adrenal insufficiency. In addition, SRY-positive mice show features of sex reversal.

**Conclusion and Outlook**

In times of more powerful genetic analysis methodologies such as next generation sequencing, modelling of genetic variants, and disease modifiers, it is becoming increasingly important to understand the clinical consequences. In vitro expression analysis of genetic variants has greatly contributed to the understanding of the molecular genetics of all forms of CAH. Mouse models of CAH have the limitation that the murine adrenal cortex does not produce androgens. However, the discovery of adrenomedullary impairment in CAH has been mainly achieved via studying murine models. Overall, it remains important to reflect that models only answer the specific question asked toward the model system. It is likely that the current revolution in genomic engineering techniques such as transcription activator like effector nucleases (TALEN) and CRISPER/ CAS9 systems will help to study the effects of complete and partial mutations inactivating steroidogenic pathways and enhance our understanding of pathophysiologic consequences by employing novel in vitro and in vivo systems.

*Clinical lead for adrenal disorders and disorders of sex development at Birmingham Children’s Hospital. His lab currently focuses on creating novel whole organism models of inborn errors of steroidogenesis by applying genomic engineering methods.*
Classic 21-hydroxylase deficiency (21OHD): Not One Simple Defect

The physiology of 21OHD fundamentally reflects a block in cortisol synthesis and diversion of cortisol precursors to androgens under ACTH stimulation. Patients with 21OHD also are prone to develop adrenal adenomas, myelolipomas, and adrenal rest tumors, most commonly in the testes. For women with classic 21OHD, genital virilization, interference with gonadal function, and low rates of fecundity add to the challenges. While some consequences might be predictable, simple models do not explain the variable disease manifestations, and current therapies do not mitigate all complications.

Traditionally, 21OHD treatment has been limited to glucocorticoids, mineralocorticoids, salt, and surgery. Replacing the adrenal insufficiency is not difficult, but normalizing the androgen excess usually requires higher and/or more frequent glucocorticoid doses, particularly to blunt the early-morning rise in ACTH and adrenal steroids. These extra doses create compliance challenges and long-term consequences from lifelong over-replacement. Genital reconstruction surgery improves many aspects of appearance and function, but the androgen effects on the brain persist, and chronic urogenital difficulties are common.

Outcomes from large 21OHD cohorts have begun to appear. The National Institutes of Health (NIH) report of 183 patients with classic and 61 patients with non-classic 21OHD found no standard treatment regimen, androgens mostly above or below the normal range, short stature, low bone mineral density in 37% of adults, and high rates of obesity and the metabolic syndrome. The British Congenital adrenal hyperplasia Adult Study Executive (CaHASE) study of 203 adults also found mostly abnormal steroid values with a tendency for over-treatment, a high prevalence of cushingoid features, low bone mineral density in 40%, obesity in 40%, markedly compromised fertility, and reduced quality of life. Similar studies from several other groups confirm these findings. Can we do better than these unflattering statistics?

Taking a step back and setting a clinical research agenda

What are the steroids and pathways that lead to virilization in the fetus, bone age advancement in the child, and impaired fertility in the adult? Ordinarily, the major 19-carbon product of the adrenal is dehydroepiandrosterone sulfate (DHEAS). Androstenedione (AD), testosterone (T), and dihydrotestosterone (DHT) are minor adrenal products; however, T and DHT arise from extra-adrenal metabolism of DHEA. DHEAS is paradoxically low-normal and easily suppressed in classic 21OHD, and recent evidence suggests that DHT in the newborn derives from the 5α-reduced “backdoor” pathway without the intermediacy of AD and T.

How should we monitor therapy at different stages of life, and what are our goals? Because 17-hydroxyprogesterone (17OHP) accumulates proximal to the block in 21OHD, 17OHP is the gold standard for diagnosis of 21OHD and is widely used to monitor treatment. Yet androgens and estrogens — not 17OHP — cause the problems. Although AD and T are used to monitor therapy, estrogen concentrations below the limits of the best commercial assays will advance bone age. Serum 17OHP is a very sensitive measure of control, but values fluctuate wildly during the day in relation to dosing, and 17OHP correlates poorly with downstream metabolites. The onset of adrenarche and puberty complicate management. In adolescents and adults, sex steroids and 17OHP also derive from the gonads, so one must estimate the contribution from the adrenal. Other steroids such as 21-deoxycortisol are more specific for 21OHD than 17OHP, and this analyte has been used to eliminate false-positive results of newborn screening and to improve diagnostic testing for non-classic 21OHD.

Why do some patients fare so well and others struggle? With the crisp enzymatic defect and the
limited number of pseudogene-derived mutations in most patients, genotype-phenotype correlations in 21OHD are strong but not perfect, even among siblings bearing the same mutations. Response to therapy is highly variable as well. Polymorphism in the genes encoding steroid and drug metabolism enzymes and changes in their expression from environmental exposures might be responsible.

Why do tumors develop? Some studies have shown absence of ACTH receptors in myelolipomas and no correlation of adrenal rest tumors with biochemical measures of control.

What are the preferred timings and procedures for reconstruction surgeries? New techniques and trends develop as soon as cohorts from the older procedures reach the stage of “long-term” follow-up.

How can we gather evidence to guide parents and patients for a rare disease with so many confounding variables? Collaborations and prospective protocols are essential.

Treatments on the horizon
Sustained-release hydrocortisone preparations are being studied. Greater convenience should improve compliance — but will control be better and complications lower? Continuous subcutaneous hydrocortisone infusion makes sense physiologically and has been shown to improve control with lower total dose in a few patients, but is this approach practical? We showed that abiraterone acetate added to replacement hydrocortisone doses normalized androgens in adult women with classic 21OHD, but the study was short. Will androgen biosynthesis inhibitors benefit children with 21OHD? With innovation and broad collaboration among clinical researchers, we can begin to answer these questions and to improve outcomes.

Fertility-Related Challenges in Females with Classic CAH
Multiple studies have demonstrated reduced fertility in females with classic CAH because of 21-hydroxylase deficiency. The birth rate in females with CAH is substantially reduced compared to the general population. It is estimated that only 25% of women with CAH ever attempt pregnancy and only 10% of those with the severe salt-wasting form. The reasons for this observation are manifold: vaginal insufficiency with dyspareunia, anovulatory menstrual cycles because of adrenal androgen excess, reduced endometrium growth during follicular phase because of adrenal progesterone production, additional ovarian hyperandrogenism (secondary polycystic ovary) because of adrenal-derived androgens in many patients, multiple psychosexual factors, or masculinization of the central nervous system due to prenatal androgen excess. One study, investigating 35 adult females with classic CAH, showed that seven were homosexual, eight were married, 13 never have had sexual intercourse, and three patients were without any sexual activity. In this cohort 18 out of 22 patients who actually had sexual intercourse reported painful penetration. The sexual function, as measured by the Female Sexual Function Index, was lower compared to controls and substantially lower in those patients with higher Prader stadium. This finding has been confirmed by a Swedish study showing that sexual life and function is perceived as less satisfactory in genotype “null.”

Most studies on fertility in female patients with CAH, however, do not take into consideration the percentage of patients indeed having attempted to conceive. Thereby, these studies do not represent the actual pregnancy rate. Having a closer look on the actual pregnancy rate in women attempting to conceive, there was no difference in women with CAH and the general population (pregnancy rate in classic CAH 91.3% versus 95.0%) and no difference in women with the salt-wasting (88.9%)
Having a closer look on the actual pregnancy rate in women attempting to conceive, there was no difference in women with CAH and the general population and no difference in women with the salt-wasting and the simple virilizing forms of classic CAH.

and the simple virilizing forms (92.9%) of classic CAH. In fact, in the majority of women, a spontaneous conception (76.2%) was achieved. Prednisolone administered once every eight hours has been shown to effectively suppress progesterone in the follicular phase and to improve receptibility of the endometrium. The treatment target for women attempting to conceive is a follicular-phase serum progesterone <2 nmol/l (<0.6 ng/ml). Prednisolone might possibly be superior to hydrocortisone in this respect, however, evidence-based data are missing. As dexamethasone passes the placenta, it should be substituted by hydrocortisone or prednisolone to avoid adrenal suppression and possible negative metabolic effects on the fetus. Dexamethasone should only be given if prenatal therapy of the fetus is wanted and warranted. It should only be implemented within the setting of a clinical trial approved by an ethics committee. During pregnancy, renin concentration physiologically increases about five-fold. In classic CAH with and without mineralocorticoid deficiency substantially elevated renin concentrations compared to healthy controls have been described. An increase of fludrocortisone in salt-wasting CAH or the addition of fludrocortisone in simple virilizing CAH may therefore be necessary and reasonable. Hoepffner, et al. described a normalization and improved conception after the addition of fludrocortisone.

Fertility-Related Challenges in Males with Classic CAH

For a long time, fertility issues in CAH have focused on females whereas males have received much less attention. In recent years, however, it has become obvious that maintaining fertility in males appears to be even more of a problem than in females. There are no data on sexuality in males with CAH. However, fertility in males is substantially reduced compared to the general population. There are two main reasons for subfertility in males: first, suppression of gonadotropins by either adrenal-derived androgens (and their conversion to estrogens) in case of under-replacement of glucocorticoids or by external glucocorticoids in case of over-replacement. Both mechanisms lead to impaired spermatogenesis and testicular atrophy.

The second major reason is testicular adrenal rest tumors. The pathogenesis of these tumors is not yet completely understood. They are thought to arise from adrenocortical remnants that have descended with the testes during fetal life or from postnatally reprogrammed Leydig cell precursors. Testicular adrenal rest tumors (TARTs) are usually bilateral and always benign. The tumors have been found to express adrenal-specific markers such as MC2-receptor, ATII-receptor, and CYP11B1. They also have been shown to be ACTH-dependent to a certain degree and thus are potentially reversible with the adrenal-suppressive therapy, dexamethasone. They are located in the rete testis and impair spermatogenesis by either mechanical obstruction of the tubuli seminiferi, or they may interfere with the local and/or systemic hormone milieu by their own hormone production. So far, no correlation of TART development and common measures of disease control in CAH has been shown. Still it is very likely that disease control plays a major role in TART growth. As surgical removal of TART has been shown to restore neither fertility nor HPA axis, surgical treatment of TART is only recommended for discomfort and pain relief and always should be testis sparing.

Fertility-Related Challenges in Females with Non-Classical CAH

The miscarriage rate in women with non-classical CAH has been shown to be substantially increased (25% versus 6% in the general population). However, it can be normalized with low to moderate doses of hydrocortisone prior to and during pregnancy, therefore, it is recommended at these times. ☎

ACKNOWLEDGEMENT: THIS ARTICLE WAS REVIEWED BY FELIX BEUSCHLEIN, MD, UNIVERSITY OF MUNICH; AND RUTH KERI, PHD, CASE WESTERN RESERVE UNIVERSITY.
Bring your biomarkers to life.
The best, most relevant Luminex® assays for metabolism & endocrinology.

For a complete picture of the role of biomarkers in metabolic disease you need to analyze data for multiple proteins from multiple systems. To help you discover the biology in your data, we’ve built the largest portfolio of multiplex and single-plex assays for endocrine and metabolic hormone biomarkers, and a complete spectrum of trusted Luminex® instrumentation.

You’ll get more from each precious sample with our analytically-validated MILLIPLEX® MAP assay panels, based on Luminex® technology. And you’ll get the same accuracy and precision in every lot, backed by the same, unwavering technical support.

Bring your research to life:
www.merckmillipore.com/milliplex

Active GLP-1 and total GLP-1 are elevated in postprandial subjects compared to fasting human subjects as measured using the MILLIPLEX® MAP Human Metabolic Hormone Panel. DPP IV inhibitor was immediately added to blood samples after sample collection.
About one in every thousand individuals will develop a pituitary adenoma, a noncancerous but disruptive tumor on the pituitary gland that can induce a variety of negative side effects. But, among these patients, approximately 5% suffer from a very particular inherited form of the disease: familial isolated pituitary adenoma (FIPA).

Márta Korbonits, MD, PhD, professor of endocrinology at the Queen Mary University of London, is searching for the origins of this genetic disorder in hopes of helping physicians diagnose it faster and provide better care for patients. Among families with FIPA, one in five cases can be traced back to the gene called aryl hydrocarbon receptor interacting protein (AIP), but for the other 80 percent of families facing the disease, the cause is still unknown.

Korbonits spoke with Endocrine News about her research and the importance of finding FIPA before its effects become irreversible.
but for the regulation of that hormone. Informing clinical practice and physiology with this two-way kind of work is really exciting.

**EN:** What are you currently working on?

**MK:** My main project at this point is working on familial pituitary adenomas. These involve patients who have a pituitary adenoma and also have a family history of this disease, although in some cases there is no known family history despite having genetic origin of the disease. One of the interesting aspects is why some people develop the disease while other family members having the same mutation are spared. We are also interested in the exact mechanism of how the mutations cause the disease.

There have been some really interesting findings regarding the phenotypes and their correlation to the exact gene mutation, or the genotype. Our study includes one of the largest groups of patients with this disease. We are combining clinical data with experimental results — identifying DNA mutation in patient samples and recreating these mutations in the lab to be able to do functional experiments.

**EN:** Among your projects, what accomplishments are you most proud of?

**MK:** I am proud that we were able to help put this disease on the table in the United Kingdom and elsewhere by identifying quite a lot of patients with pituitary adenomas and screening their families for the disease as well. We were able to provide genetic advisement for patients and, via screening, sometimes discovered patients who did not even realize that they had the disease. If we can interfere earlier, we hopefully have a better chance to cure or successfully treat the pituitary adenoma. So I am glad we were able to help in this regard.

My most publicized work was a project involving a patient born 250 years ago in Northern Ireland. We identified the mutation in him and also identified families living with the same disease, and then turned to his relatives who are alive today. After that, we did a whole population screening of the community he was from and identified some additional cases. Hopefully, this made [the community] aware of the disease so that it can be recognized sooner.

**EN:** If you had unlimited funding, how would you use it to enhance your laboratory and research?

**MK:** I would screen patients whose clinical picture suggests that they have this particular disease and use the resources to analyze all of our existing samples. We have many additional samples that we would like to analyze.

**EN:** Where do you see your scientific work heading in the future? How do you hope to affect change with your projects?

**MK:** I see identifying these new genes as the next step in this work. The other important step is to identify the mechanism of how the genes work and eventually develop new types of treatments and methods for diagnosing the disease sooner.

**EN:** Any final thoughts you would like to share with our readers?

**MK:** If you have a patient or multiple patients with familial pituitary adenomas, please do not hesitate to contact me. FIPA is a relatively rare disease, and lots of patients have been told in the past that it is not familial but, in some cases, it actually is. *(Those working with patients that have been diagnosed with familial pituitary adenoma can get in touch with Korbonits at m.korbonits@qmul.ac.uk.)*

If we can interfere earlier, we hopefully have a better chance to **cure or successfully treat** the pituitary adenoma.

More information on FIPA can be found at www.fiapatiens.org.
Your Go-To Source is Now Online

The new Endocrine News website gives you the best features of an online magazine — great design with a robust, interactive, and personalized experience. Find all of the cutting-edge content you expect from Endocrine News online with regular updates on hot topics and the latest news in endocrinology.

If it’s important to you, it’s on endocrinnews.org

Visit endocrinnews.org often to stay up-to-date with the latest news in endocrinology.

Follow Us on Twitter @Endocrine_News

SPECIAL ARTICLE SERIES
IN ENDOCRINOLOGY ON PRENATAL PROGRAMMING

DEVELOPMENTAL PROGRAMMING, STRESS, AND DISEASE: HIGHLIGHTS OF THE PRENATAL PROGRAMMING AND TOXICITY (PPTOX) IV MEETING

Visit Endocrinology online for a special series on the role of environmental stressors on hormones during pregnancy and the increased probability of disease or dysfunction of the fetus as a result of early exposure.

For the complete collection of articles, plus a podcast discussion of the state of the science of Developmental Origins of Health and Disease (DOHaD), and the related topic of endocrine-disrupting chemicals (EDCs) visit press.endocrine.org/pptoxiv.
A key issue that the U.S. Congress must resolve by September 30 (the end of the fiscal year) is how to fund the government and all federal programs, including the National Institutes of Health (NIH). Although appropriations bills were able to be passed by committees in both the House and the Senate, neither body has been able to bring this legislation to a full vote. Prior to leaving Washington for the August congressional recess, Senate Majority Leader Mitch McConnell (R-KY) reported that legislators “haven’t even begun to plan how to cover the government’s funding after the fiscal year ends on September 30.” The House will be in session for only 10 days in September (the Senate has 15 days scheduled).

Democrats in the Senate have effectively shut down the process by blocking consideration of any bills that fund programs at the reduced sequester levels. At the same time, a debate over the Confederate Flag on federal grounds has deterred House leadership from bringing up the remaining bills on their side. Then, of course, there is the blanket veto threat from President Obama, which has all but guaranteed that these bills would never be enacted under current levels. Adding to the gridlock, a number of Republican leaders have “threatened to reject” a spending bill “needed to keep the government open” unless funding for Planned Parenthood is removed.

Therefore, the Congress has the following options: Lawmakers could negotiate a deal that provides sequestration relief, if only on a partial and/or temporary basis. They could do a continuing resolution (a mechanism that would fund programs at current levels/no increases) that is either short term or year long, and/or they could risk a government shutdown.

**TAKE ACTION:**
Now is a critical time to contact your members of Congress and urge support for a deal on the budget that will give some relief to research funding. Please visit the Society’s online advocacy campaign at [www.endocrine.org/advocacy](http://www.endocrine.org/advocacy) to contact Congress.
In recent months, Endocrine Society members and staff have worked with the office of Sen. Dianne Feinstein (D-CA) on legislative efforts to improve the regulatory oversight of personal care products, such as cosmetics, shampoos, and lotions. On April 20, Sen. Feinstein and Sen. Susan Collins (R-ME) introduced S.1014, the Personal Care Products Safety Act (PCPSA). The bill prioritizes several chemicals commonly used in personal care products for immediate review by the FDA. One of the priority chemicals, propyl paraben, is highlighted as an endocrine-disrupting chemical (EDC) that can mimic estrogen and is “linked to a wide range of health effects, including reproductive system disorders.”

The Endocrine Society was encouraged that the PCPSA sets a rigorous safety standard for FDA review of chemicals and includes provisions to allow public access to product statements. The Society joined the Environmental Working Group, Society for Women’s Health Research, and other consumer health organizations in endorsing the Personal Care Products Safety Act. The Society believes that this bill will help ensure a safe marketplace for personal care products and reduce harms from exposure to toxic chemicals such as EDCs, and we will continue to work with Sen. Feinstein to advance the legislation and other efforts to support public health. In September, the Endocrine Society will participate in a congressional briefing to raise awareness of the PCPSA and encourage committee consideration of the legislation.

Remembering EDC Research Pioneer Louis J. Guillette, Jr.

The world of endocrine-disrupting chemical research recently lost a giant in the field with the passing of Louis J. “Lou” Guillette, 60.
As part of the Endocrine Society’s comprehensive advocacy program, the Society submits comments on Requests for Information (RFIs) from the National Institutes of Health (NIH) and other research funding agencies. This summer, the NIH issued RFIs on biomedical technology development and health disparities research, two topics of great interest to endocrinologists.

Technology Development

On June 10, the National Institute of General Medical Sciences (NIGMS) issued a RFI on “innovative approaches to technology development for the biomedical research community.” NIGMS is considering efforts to both support the development of new technologies and how best to ensure broad access to newly developed technologies. In response to the RFI, the Endocrine Society identified several challenges that researchers face in the generation, development, and application of new technologies. For example, researchers are forced to continuously update equipment and expertise in response to new technological developments, evaluate multiple expensive and time-consuming approaches to experiments, and navigate numerous new resources, databases, and biobanks.

The Endocrine Society recommended that the NIH continue to develop and encourage the use of centralized resources that help researchers quickly access databases and analyze data. The Society also encouraged the NIH to seek new ways to foster connections between basic and clinical researchers, and explore the use of public-private partnerships to create user-friendly data mining tools and support applied biomedical research.

Health Disparities Research

The National Institute on Minority Health and Health Disparities (NIMHD) is embarking on a scientific planning process in collaboration with other NIH institutes and centers to define a vision that will guide the development of the science of health disparities research for the next decade. On April 17, the NIMHD issued a RFI “Soliciting Input into the NIH Science Vision for Health Disparities Research.” In response to the RFI, the Endocrine Society highlighted infrastructure and resource needs for teams that study health disparities, scientific advances that should be prioritized in the vision, and policy considerations to reduce barriers to effective care.

The Society’s response also highlighted the Endocrine Society’s Scientific Statement on Health Disparities in Endocrine Disorders as an important resource the NIH should reference to identify key questions that should be addressed by additional research. We anticipate that the Science Vision for Health Disparities Research will be an important tool to reduce health disparities in the coming decade and staff will continue to seek opportunities to engage with the NIH and the NIMHD as the Science Vision develops.
As part of a comprehensive approach to enhance the visibility of endocrinology among research funding agencies, the Society participated in the June 4 meeting of the National Advisory Child Health and Human Development (NACHHD) Council. The Council advises the director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) on research, support activities, and functions of the institute.

During the director’s report, NICHD director Alan Guttmacher, MD, provided updates on several projects of interest to the extramural research community. Guttmacher highlighted a new online system, the NICHD Data and Specimen Hub (N-DASH), which will allow the storage and access of de-identified data from NICHD-supported studies. The N-DASH platform launched in late June with data from 14 initial studies. The director then noted that they are closer to delivering an interactive mobile app to develop crowd-sourced data to detail the natural history and variations of human pregnancy. The app will also allow women to receive accurate information about pregnancy from trusted sources and let pregnant women know about opportunities to participate in research. Additionally, Guttmacher announced the launch of a new Spanish-language website to broaden community outreach.

The Council was joined by the director of the National Institute for General Medical Studies (NIGMS), Jon Lorsch, PhD, to discuss NIGMS’ efforts to refocus its portfolio on investigator-initiated research. Lorsch described the institute’s rationale for increasing the funding of “programs” rather than “projects” through the institute’s Maximizing Investigator’s Research Award (MIRA) program. Specifically, the institute’s data suggest that research funding is skewed toward a top tier of researchers, and that additional efficiencies might be enabled through a more equitable distribution of funds, for example, by reducing investigator time spent writing grant applications. The MIRA program proposes to award grants of up to $750,000 per year for up to five years.

However, the awards will be open to established investigators with at least two existing R01 grants who make the MIRA award their primary source of funding. This implies that researchers will be comfortable trading a greater overall dollar amount for additional efficiency and funding security. The NICHD has established a working group to consider whether to implement a similar program through the R35 mechanism. The working group is weighing many options, including identifying a target career stage and evaluating how many awards NICHD should support through this mechanism.

In a separate concept clearance and review session, the three proposals shown in the table below were discussed by the Council and passed with no objection. Concept clearance represents an early step in the process of developing Requests for Application and Program Announcements, and the final details and eventual publication are subject to additional approval. — Joe Laakso, PhD, associate director, science policy

<table>
<thead>
<tr>
<th>PROGRAM NAME</th>
<th>FUNDING MECHANISM</th>
<th>PROGRAM CONTACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population Dynamics Centers Research Infrastructure FY 2016–2020</td>
<td>P2C</td>
<td>Rebecca L. Clark, PhD, Population Branch Dynamics</td>
</tr>
<tr>
<td>Specialized Centers for Research in Pediatric Developmental Pharmacology</td>
<td>U54</td>
<td>Ekaterini Tsiolou, MD, Obstetric and Pediatric Pharmacology and Therapeutics Branch</td>
</tr>
<tr>
<td>Omics Approaches to Assess Human Placental Development and Function in Real Time</td>
<td>R01/R21</td>
<td>David Weinberg, PhD, Office of the Director</td>
</tr>
</tbody>
</table>
SAVE THE DATES

April 1 – 4, 2016
(Friday – Monday)
Boston Convention and Exhibition Center,
Boston, Mass.

- Abstract submission:
  September 9, 2015 –
  November 10, 2015
- Early registration:
  October 6, 2015 –
  January 13, 2016
- Advance registration:
  January 14, 2016 –
  February 25, 2016
- Late-breaking abstract submission:
  January 19, 2016 –
  February 17, 2016
- Housing reservation deadline:
  March 8, 2016

The most important innovations and latest insights in endocrinology will hit the East Coast Friday, April 1 – Monday, April 4, as ENDO 2016 lands in Boston. Join leading practitioners and researchers from around the world for four exhilarating days of education and networking.

Celebrate the Society’s Centennial

The Society has come a long way from June 1916 when a group gathered at the American Medical Association’s meeting to explore creating a professional society for those working in the fledgling field of endocrinology. That discussion resulted in the founding of the Association for the Study of Internal Secretions with 300 charter members. Do you know what year the name was changed to the Endocrine Society? Learn the answer to this and more as we celebrate the legacy of the Society through special historical perspectives in the key areas of scientific discovery that encompass endocrinology.

Submit Your Abstract for ENDO 2016

Abstract submissions are now being accepted. Submit your work and reserve your place in beautiful Boston. Visit endo2016.org for complete details on abstract submission. See you in April!

A Mecca for Endocrinologists

Boston is a training hub for endocrinology and many members have trained or worked in this charming historical area. ENDO 2016 takes place at the Boston Convention & Exhibition Center — the largest convention center in the Northeastern U.S. and a technological marvel. Come and enjoy all Boston has to offer while you reconnect with colleagues from around the world.

A Wealth of Opportunities

ENDO 2016 will present thought-provoking speakers in insightful sessions, and the opportunity for you to explore all of the key areas of endocrinology from basic discoveries to clinical applications. The networking at ENDO makes the meeting a can’t-miss event every year.

In addition to the outstanding presentations, there will be pre-conference events starting on Thursday, March 30, and ENDOExpo will provide information on the latest advances in products and services for ENDO attendees.
ENDOCRINE CASES: Timely Advice from Experts in the Field

The Endocrine Society offers members an exclusive benefit — Endocrine Cases. Envisioned and developed by immediate past president Richard J. Santen, MD, this online tool allows members to submit their most challenging clinical cases and have Society experts weigh in. Present real or hypothetical situations, and test your hypothesis against what the experts recommend. Visit endocrine.org/Cases to learn more about this valuable and informative member benefit.

New Diabetes Management Program from HHN

In November, the Hormone Health Network (HHN) will launch a new collaborative diabetes management program called Diabetes Awareness Information for Loved Ones and You (D.A.I.L.Y.) aimed at patients as well as clinicians who treat diabetes.

D.A.I.L.Y. will provide resources that are tailored to an individual patient’s needs and can be shared with healthcare professionals to encourage a collaborative approach to diabetes management. Users enroll as a person with diabetes, family member or friend of a person with diabetes, or as a healthcare professional. The goal is to provide access to useful educational resources that are tools not rules for diabetes self-management. As the leading experts in diabetes treatment, endocrinologists helped to develop program content to ensure patients and their loved ones receive the most trusted information.

Ahead of the launch, HHN has released the new logo for D.A.I.L.Y., which was created with input from diabetes experts, Endocrine Society membership and staff, and, more importantly, using patients’ input and uses the sun itself as a centerpiece, according to HHN director, Cheretta Clerkley. “The sun is a symbol of warmth, light, hope, knowledge, and awareness,” she says. “The logo conveys what we hope patients and healthcare professionals will gain from enrollment in this program, which we hope will be a more humanistic, positive, and approachable feel toward taking control of diabetes management.”

For more information about D.A.I.L.Y. or to pre-enroll, visit, www.hormone.org/about-us/volunteer/diabetes-you.
In July, the Society issued a Clinical Practice Guideline (CPG) on strategies for treating Cushing’s syndrome entitled Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, which was published online and appeared in the August issue of The Journal of Clinical Endocrinology & Metabolism (JCEM).

Cushing’s syndrome occurs when a person has excess cortisol in the blood for an extended period, according to the Hormone Health Network. When it is present in normal amounts, cortisol is involved in the body’s response to stress, maintains blood pressure and cardiovascular function, keeps the immune system in check, and converts fat, carbohydrates, and proteins into energy. Chronic overexposure to the hormone can contribute to the development of cardiovascular disease, infections, and blood clots in veins.

In some cases, tumors found on the adrenal or pituitary glands or elsewhere in the body cause the overproduction of cortisol and lead to the development of Cushing’s syndrome. The CPG focus on this form of the condition, known as endogenous Cushing’s syndrome.

“People who have active Cushing’s syndrome face a greater risk of death — anywhere from nearly twice as high to nearly five times higher — than the general population,” says Lynnette K. Nieman, MD, of the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development in Bethesda, MD, and chair of the task force that authored the guideline. “To reduce the risk of fatal cardiovascular disease, infections, or blood clots, it is critical to identify the cause of the Cushing’s syndrome and restore cortisol levels to the normal range.”

In the CPG, the Endocrine Society recommends that the first-line treatment for endogenous Cushing’s syndrome be the removal of the tumor unless surgery is not possible or unlikely to address the excess cortisol. Surgical removal of the tumor is optimal because it leaves intact the hypothalamic-pituitary-adrenal axis, which is integral to the body’s central stress response.

Other members of the Endocrine Society task force who developed this CPG include: Beverly M.K. Biller of Massachusetts General Hospital, in Boston, Mass.; James W. Findling of the Medical College of Wisconsin, in Milwaukee, Wisc.; M. Hassan Murad of the Mayo Clinic, in Rochester, Minn.; John Newell-Price of the University of Sheffield, in Sheffield, U.K.; Martin O. Savage of the William Harvey Research Institute at Barts and the London School of Medicine and Dentistry, in London, U.K.; and Antoine Tabarin of CHU de Bordeaux and INSERM at the University of Bordeaux, in Bordeaux, France.

The CPG was co-sponsored by the European Society of Endocrinology. 

In the CPG, the Endocrine Society recommends that the first-line treatment for endogenous Cushing’s syndrome be the removal of the tumor unless surgery is not possible or unlikely to address the excess cortisol.
LAST CALL

VOTE

2016 ELECTION

TIME IS RUNNING OUT TO VOTE.

Election ballots were sent to members with voting privileges in early September 2015. Information for online voting can be accessed by visiting endocrine.org/election.

Questions should be directed to Elizabeth Kan at 202.971.3621 or ekan@endocrine.org.

ELECTRONIC VOTES MUST BE RECEIVED BY MIDNIGHT EST ON OCTOBER 12, 2015.
What You Should Know About

SHARED DECISION MAKING (SDM)

Shared Decision Making gets patients involved in their healthcare treatment plan. SDM takes into account the best scientific evidence and the values and preferences of the patient to provide the most effective therapy possible. For better patient outcomes, consider implementing an SDM plan in your practice.

WHY SDM?

• Improve patient satisfaction and involvement with their care
• Help patients assume greater responsibility for health care decisions
• Promote compliance and adherence to treatment regimens
• Empower patients to be more knowledgeable and active in managing their care

EVIDENCE FOR SDM

• Reduction in use of tests
• Reduction in elective procedures and their costs
• Better health outcomes
• Lower litigation rates

The Hormone Health Network is the nation’s endocrine patient education resource. We are committed to helping patients have more informed discussions with their health care providers about hormone health, disease, and treatment. All of our educational resources are free and based on the clinical and scientific expertise of the Endocrine Society.

**WHAT DO PATIENTS THINK?**
- Strong desire to engage in SDM about treatment options
- Multiple barriers inhibit conversation with physicians about health decisions
- Feel compelled to confirm to socially sanctioned roles and defer to physicians
- Physicians can be authoritarian
- Fear of being categorized “difficult” prevents patients from participating more fully in their own health care
  
  *(Frosch, et al. Health Affairs, 2012)*

**IMPACT ON COSTS**
- Lewin Group estimated SDM for 11 procedures saved $9 BILLION nationally over 10 years
- Group Health used SDM for hip or knee replacement: 38% fewer knee and 26% fewer hip surgeries, **COST LOWERED BY 12–21% OVER 6 MONTHS.**

**BEST PRACTICES FOR IMPLEMENTING SDM**

1. **Establish ongoing partnership** (trust, mutual respect)
2. **Foster two-way information exchange** between the physician and the patient
3. **Support a process of deliberation**; patients encouraged to express preferences
4. **Make a decision** that honors provider’s expert knowledge and respects patient’s individual needs

**SHARED DECISION MAKING STAGES**

*Visit hormone.org today to access aides to empower and educate your patients.

Shared Decision Making tools specific to diabetes can be accessed at accurateinsulin.org.*
Free to Decide
James Magner, M.D.

• Amusing and instructive anecdotes about becoming a scientific endocrinologist in and out of academics.

• See how to survive training and join a faculty while keeping the family strong.

• Learn pros and cons of working in biotech.

• Avoid being weighed down by the common view among many scientists that life may have no ultimate meaning, and man may lack free will.

• Enjoy hobbies such as chess and poker.
   (Author’s poker tournament winnings >$320,000.)

Available at Amazon.com and other fine bookstores.

---

FAES Endocrinology Update & Review Course at NIH
October 12 - 16, 2015
Double Tree Hotel | 8120 Wisconsin Ave. | Bethesda, MD | 20814

Course Purpose
Intended for physicians preparing for the Endocrinology Board Examination, and physicians certified in Endocrinology who wish to remain abreast of recent field advances.

Register:
faestraining.org/index.php/conferences-bootcamps
Email: registration@faes.org | Telephone (301) 451-1434

Tuition
Physicians: $1,395.00
Fellows/Other Medical Professionals: $895.00
Manual Only: $595.00

---

Endocrinologist-
Prestigious multi-specialty practice in a desirable NJ university town is seeking a BC/BE Endocrinologist to join a busy Endocrinology department. Excellent opportunity leading to partnership. Fax CV to Joan Hagadorn at 609-430-9481, or email CV to jhagadorn@msn.com
VISIT ENDO2016.ORG TO SUBMIT YOUR ABSTRACT TODAY AND LEARN MORE ABOUT TRAVEL AWARDS.

ABSTRACT SUBMISSION DEADLINE:
NOVEMBER 10, 2015, 1:00 PM ET

SHARE YOUR KNOWLEDGE AND EXPERIENCE BY SUBMITTING YOUR BEST SCIENCE FOR ORAL, POSTER, AND POSTER PREVIEW PRESENTATION DURING ENDO 2016 — THE PREMIER VENUE TO SHARE RESEARCH, EXCHANGE IDEAS, AND NETWORK WITH THOUSANDS OF ENDOCRINE RESEARCHERS AND PRACTITIONERS.
Type 2 Diabetes:
- The recommended starting dose of TOUJEO in insulin naïve patients with type 2 diabetes is 0.2 units per kilogram of body weight once daily. The dosage of other anti-diabetic drugs may need to be adjusted when starting TOUJEO to minimize the risk of hypoglycemia [See Warnings and Precautions (5.3)].

2.3 Starting Dose in Patients with Either Type 1 or Type 2 Diabetes Already On Insulin Therapy
- To minimize the risk of hypoglycemia when changing patients from a once daily long-acting or intermediate acting insulin product to TOUJEO, the starting dose of TOUJEO can be the same as the once daily long-acting dose. For patients controlled on LANTUS (insulin glargine, 100 units/mL) expect that a higher daily dose of TOUJEO will be needed to maintain the same level of glycemic control [See Clinical Pharmacology (12.2) in the full prescribing information and Clinical Studies (14.1) in the full prescribing information].
- To minimize the risk of hypoglycemia when changing patients from twice-daily NPH insulin to once-daily TOUJEO, the recommended starting TOUJEO dose is 90% of the total daily NPH insulin dosage.
- To minimize the risk of hypoglycemia when changing patients to TOUJEO, monitor glucose frequently in the first weeks of therapy titer the dose of TOUJEO per instructions and the dose of other glucose lowering therapies per standard of care. [See Warnings and Precautions (5.2) and Clinical Pharmacology Section (12.2) in the full prescribing information].

2.4 Important Administration Instructions
- Prior to initiation of TOUJEO, patients should be trained by their healthcare professional on proper use and injection technique. Training reduces the risk of administration errors such as needle sticks and incomplete dosing.
- Patient should follow the Instructions for Use to correctly use the pen device and administer TOUJEO.
- Patients should be informed that the dose counter of the TOUJEO SoloStar disposable prefilled pen should align with the dose of units of TOUJEO to be injected. The TOUJEO SoloStar prefilled pen has been specifically designed for TOUJEO, therefore no dose conversion is required [Patient counseling information (17) in the full prescribing information].

5.3 Hypoglycemia

5.4 Medication Errors
Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between TOUJEO and other insulins, instruct patients to always check the insulin label before each injection.

5.5 Hypersensitivity and Allergic Reactions
Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including TOUJEO. If hypersensitivity reactions occur, discontinue TOUJEO; treat per standard of care and monitor until symptoms and signs resolve [See Adverse Reactions (6)]. TOUJEO is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients [See Contraindications (4)].

5.6 Hypokalemia
All insulin products, including TOUJEO, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).

5.7 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists
Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including TOUJEO, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.

5.8 Hyperglycemia

6. ADVERSE REACTIONS

The data in Table 1 reflect the exposure of 204 patients with type 1 diabetes to TOUJEO with mean exposure duration of 23 weeks. The type 1 diabetes population had the following characteristics: Mean age was 46 years and mean duration of diabetes was 21 years. Fifty five percent were male, 86% were Caucasian, 5% were Black or African American and 5% were Hispanic. At baseline, the mean eGFR was 82 mL/min/1.73m² and 35% of patients had eGFR<60 mL/min/1.73m². The mean BMI was 28 kg/m². Hba1c at baseline was greater or equal to 8% in 59% of patients.

The data in Table 2 reflect the exposure of 1242 patients with type 2 diabetes to TOUJEO with mean exposure duration of 25 weeks. The type 2 diabetes population had the following characteristics: Mean age was 59 years and mean duration of diabetes was 13 years. Fifty three percent were male, 88% were Caucasian, 7% were Black or African American and 17% were Hispanic. At baseline, mean eGFR was 79 mL/min/1.73m² and 27% of patients had an eGFR<30 mL/min/1.73m². The mean BMI was 35 kg/m². Hba1c at baseline was greater or equal to 8% in 66% of patients.

Common adverse reactions were defined as reactions occurring in ≥5% of the population studied. Common adverse reactions occurring for TOUJEO-treated subjects during clinical trials in patients with type 1 diabetes mellitus and type 2 diabetes mellitus are listed in Table 1 and Table 2, respectively. Hypoglycemia is discussed in a dedicated subsection below.

Table 1: Adverse reactions in two pooled clinical trials of 26 weeks and 16 weeks duration in adults with type 1 diabetes (with incidence ≥5%)

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>TOUJEO® + mealtine insulin*, % (n=304)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasopharyngitis</td>
<td>12.8</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>9.5</td>
</tr>
</tbody>
</table>

*“mealtine insulin” refers to insulin glulisine, insulin lispro, or insulin aspart

Table 2: Adverse reactions in three pooled clinical trials of 26 weeks duration in adults with type 2 diabetes (with incidence ≥5%)

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>TOUJEO®, % (n=1,242)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasopharyngitis</td>
<td>7.1</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>5.7</td>
</tr>
</tbody>
</table>

*one of the trials in type 2 diabetes included mealtine insulin

Risk Factors for Hypoglycemia

The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulation. As with all insulin preparations, the glucose lowering effect time course of TOUJEO may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature [See Clinical Pharmacology (12.2) in the full prescribing information]. Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., nutrient content or timing of meals), changes in level of physical activity, or changes to co-administered medication [See Drug Interactions (7)]. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use in Specific Populations (8.5, 8.6)].
Hypoglycemia
Hypoglycemia is the most commonly observed adverse reaction in patients using insulin, including TOUJEO [See Warnings and Precautions (5.3)]. In the TOUJEO program, severe hypoglycemia was reported as an event requiring assistance of another person to administer resuscitative action and documented symptomatic hypoglycemia was defined as an event with typical symptoms of hypoglycemia accompanied by a self-monitored or plasma glucose value equal to or less than 54 mg/dL.

The incidence of symptomatic hypoglycemia in patients with type 1 diabetes receiving TOUJEO as part of a multiple daily injection regimen was 6.6% at 26 weeks. The incidence of documented symptomatic hypoglycemia was 69% at 26 weeks. There were no clinically important differences in hypoglycemia between TOUJEO and LANTUS among type 1 diabetes patients. The incidence of severe hypoglycemia in patients with type 1 diabetes was 5% at 26 weeks in patients receiving TOUJEO as part of a multiple daily injection regimen, and 1.0% and 0.9% respectively at 26 weeks in the two studies where patients received TOUJEO as part of a basal-insulin only regimen. The incidence of documented symptomatic hypoglycemia in patients with type 2 diabetes receiving TOUJEO ranged from 6% to 37% at 26 weeks and the highest risk was again seen in patients receiving TOUJEO as part of a multiple daily injection regimen. Insulin initiation and intensification of glucose control Intensification or rapid improvement in glucose control has been associated with a transient, reversible hypothyroidism disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk of diabetic retinopathy and neuropathy.

Peripheral Edema
Insulin, including TOUJEO, may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.

Lipodystrophy
Long-term use of insulin, including TOUJEO, can cause lipodystrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) in some patients and may affect insulin absorption [See Dosage and Administration (2.1)].

Weight gain
Weight gain has occurred with some insulin therapies including TOUJEO and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.

Allergic Reactions
Some patients taking insulin therapy, including TOUJEO have experienced urticaria, local edema, and pruritus at the site of injection. These conditions were usually self-limiting. Severe cases of generalized allergy (anaphylaxis) have been reported [See Warnings and Precautions (5.3)].

Cardiovascular Safety
No clinical studies to establish the cardiovascular safety of TOUJEO have been conducted. A cardiovascular outcomes trial, ORIGIN, has been conducted with LANTUS. It is unknown whether the results of ORIGIN can be applied to TOUJEO.

The Outcome Reduction with Initial Glargine Intervention trial (i.e., ORIGIN) was an open-label, randomized, 12,537 patient study that compared LANTUS to standard care on the time to first occurrence of a major adverse cardiovascular event (MACE). MACE was defined as the composite of death from cardiovascular and non-cardiovascular causes, myocardial infarction and non-fatal stroke. The incidence of any MACE was similar between LANTUS and standard care in ORIGIN [Hazard Ratio (95% CI) for MACE: 1.02 (0.94, 1.11)].

In the ORIGIN trial, the overall incidence of cancer (all types combined) [Hazard Ratio (95% CI); 0.93 (0.89, 1.11)] or death from cancer [Hazard Ratio (95% CI); 0.94 (0.77, 1.15)] was also similar between treatment groups.

7.2 Immunogenicity
As with all therapeutic proteins, there is potential for immunogenicity.

In a 6-month study of type 1 diabetes patients, 79% of patients who received TOUJEO once daily were positive for anti-insulin antibodies (AIA) at least once during the study, including 22% that were positive at baseline and 44% of patients who developed anti-drug antibody [i.e., anti-insulin glargine antibody (ADA)] during the study. Eighty percent of the AIA positive patients on TOUJEO who developed ADA were positive at baseline, remained ADA positive at baseline, and developed ADA during the study. In a 26-week study of type 2 diabetes patients, 25% of patients who received TOUJEO once daily were positive for AIA at least once during the study, including 42% who were positive at baseline and 20% of patients who developed ADA during the study. Ninety percent of the AIA positive patients on TOUJEO with antibody test at baseline, remained AIA positive at month 6. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay and may be influenced by several factors such as: assay methodology, sample handling, timing of sample collection, concomitant medication, and underlying disease. For these reasons, comparison of the incidence of antibodies to TOUJEO with the incidence of antibodies in other studies or to other products, may be misleading.

7.3 Drugs That May Increase the Risk of Hypoglycemia
The risk of hypoglycemia associated with TOUJEO use may be increased with antidepressant agents, (ACE) inhibitors, angiotensin II receptor blocking agents, disopyramide, fribates, fluvoxetin, monoxide oxidase inhibitors, pentoxifylline, pramipexole, propylphzone, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Dose adjustment and increased frequency of glucose monitoring may be required when TOUJEO is co-administered with these drugs.

7.4 Drugs That May Decrease the Blood Glucose Lowering Effect of TOUJEO
The glucose lowering effect of TOUJEO may be decreased when co-administered with atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, daniol, diuretics, estrogens, glucocorticoids, heparin, niacin, niacin analogs (e.g., nicotinic acid), oral contraceptives (oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline) and thyroid hormones. Dose adjustment and increased frequency of glucose monitoring may be required when TOUJEO is co-administered with these drugs.

7.5 Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of TOUJEO
The glucose lowering effect of TOUJEO may be increased or decreased when co-administered with alcohol, beta-blockers, clindamycin, and lithium salts. Pentamide may cause hypoglycemia, which may sometimes be followed by hyperglycemia. Dose adjustment and increased frequency of glucose monitoring may be required when TOUJEO is co-administered with these drugs.

7.6 Drugs That May Affect Signs and Symptoms of Hypoglycemia
The signs and symptoms of hypoglycemia [see Warnings and Precautions (5.3)] may be blunted when beta-blockers, clindamycin, gualenethidine, and reserpine are co-administered with TOUJEO.

8. USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or a history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. In patients with diabetes or gestational diabetes, insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. Careful monitoring of glucose control is essential in these patients. Therefore, female patients should be advised to tell their physicians if they intend to become, or if they become pregnant while taking TOUJEO.

Human data
There are no clinical studies of the use of TOUJEO in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Animal data
Subcutaneous reproduction and teratology studies have been performed with insulin glargine and regular human insulin in rats and Himalayan rabbits. Insulin glargine was given to female rats before mating, during mating, and throughout pregnancy at doses up to 0.36 mg/kg/day, which is approximately 50 times the recommended human subcutaneous starting dose of 0.2 Units/kg/day (0.007 mg/kg/day), were administered during organogenesis. The effects of insulin glargine did not generally differ from those observed with regular human insulin in rats or rabbits. However, in rabbits, five fetuses from two litters of the high-dose group exhibited dilation of the cerebral ventricles. Fertility and early embryonic development appeared normal.

8.2 Nursing Mothers
Endogenous insulin is present in human milk. It is unknown whether insulin glargine is excreted in human milk. Because many drugs, including human insulin, are excreted in human milk, caution should be exercised when TOUJEO is administered to a nursing woman. Use of TOUJEO is compatible with breastfeeding, but women with diabetes who are lactating may require adjustments of their insulin doses.

8.3 Pediatric Use
The safety and effectiveness of TOUJEO have not been established in pediatric patients.

8.4 Pediatric Use
In controlled clinical studies, 30 of 304 (9.8%) TOUJEO treated patients with type 1 diabetes and 327 of 1242 (26.3%) TOUJEO treated patients with type 2 diabetes were ≥65 years of age, among them 20.9% of the patients with type 1 and 30.0% of the patients with type 2 diabetes were ≥75 years of age. No overall differences in effectiveness and safety were observed in the subgroup analyses across the age groups. Nevertheless, caution should be exercised when TOUJEO is administered to geriatric patients. In elderly patients with diabetes, the initial dose, dose increments, and maintenance dosage should be conservative to avoid hypoglycemia [See Warnings and Precautions (5.3), Adverse Reactions (6) and Clinical Studies (14) in the full prescribing information].

8.5 Geriatric Use
The effect of hepatic impairment on the pharmacokinetics of TOUJEO has not been studied. Frequent glucose monitoring and dose adjustment may be necessary for patients in hepatic impairment [See Warnings and Precautions (5.3)].

8.6 Hepatic Impairment
The effect of renal impairment on the pharmacokinetics of TOUJEO has not been studied. Frequent glucose monitoring and dose adjustment may be necessary for patients in renal impairment [See Warnings and Precautions (5.3)].

8.7 Renal Impairment
The effect of renal impairment on the pharmacokinetics of TOUJEO has not been studied. Some studies with human insulin have shown increased circulating levels of insulin in patients with renal failure. Frequent glucose monitoring and dose adjustment may be necessary for TOUJEO in patients with renal impairment [See Warnings and Precautions (5.3)].

8.8 Obesity
No overall differences in effectiveness and safety were observed in subgroup analyses based on BMI.

10. OVERDOSAGE
Excess insulin administration may cause hypoglycemia and hypokalemia [see Warnings and Precautions (5.3, 5.6)]. Mild episodes of hypoglycemia can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or physical activity level may be needed. More severe episodes of hypoglycemia with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.

sanofi-aventis U.S. LLC
Bridgewater, NJ 08807
A SANOFI COMPANY
©2015 sanofi-aventis U.S. LLC

GLR-BPLR-AS-FEB15
Revised: February 2015

LANTUS, TOUJEO and SoloStar are registered trademarks of sanofi-aventis U.S. LLC.